Evidence map›Paper›PMID 34796738›Full record

ArticleJournal of the American Heart Association2021

Risk Classification for Metabolic Syndrome and the Incidence of Cardiovascular Disease in Japan With Low Prevalence of Obesity: A Pooled Analysis of 10 Prospective Cohort Studies.

Hiroyasu Iso, Renzhe Cui, Iseki Takamoto, Masahiko Kiyama, Isao Saito, Tomonori Okamura, Yoshihiro Miyamoto, Aya Higashiyama, Yutaka Kiyohara, Toshiharu Ninomiya and 16 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Guideline
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Prevalence of Metabolic Syndrome in Patients with Type 2 Diabetes in Japan: A Retrospective Cross-Sectional Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 18 institutions in 1 country.

Hiroyasu IsoPublic Health Department of Social Medicine Osaka University Graduate School of Medicine Osaka Japan.ORCID 0000-0002-9241-7289
Renzhe CuiPublic Health Department of Social Medicine Osaka University Graduate School of Medicine Osaka Japan.ORCID 0000-0002-3146-5340
Iseki TakamotoDepartment of Diabetes and Metabolic Diseases Graduate School of Medicine The University of Tokyo Hospital Tokyo Japan.
Masahiko KiyamaOsaka Center for Cancer and Cardiovascular Disease Prevention Osaka Japan.
Isao SaitoDepartment of Public Health and Epidemiology Faculty of Medicine Oita University Oita Japan.
Tomonori OkamuraDepartment of Preventive Medicine and Public Health Keio University School of Medicine Tokyo Japan.ORCID 0000-0003-0488-0351
Yoshihiro MiyamotoPreventive Cardiology National Cerebral and Cardiovascular Center Osaka Japan.ORCID 0000-0002-1337-0508
Aya HigashiyamaPreventive Cardiology National Cerebral and Cardiovascular Center Osaka Japan.ORCID 0000-0002-2172-5989
Yutaka KiyoharaHisayama Research Institute for Lifestyle Diseases Fukuoka Japan.
Toshiharu NinomiyaDepartment of Epidemiology and Public Health Graduate School of Medicine Kyushu University Fukuoka Japan.ORCID 0000-0003-1345-9032
Michiko YamadaDepartment of Clinical Studies Radiation Effects Research Foundation Hiroshima Japan.
Hideaki NakagawaDepartment of Social and Environmental Medicine Kanazawa Medical University Ishikawa Japan.
Masaru SakuraiDepartment of Social and Environmental Medicine Kanazawa Medical University Ishikawa Japan.
Michio ShimabukuroDepartment of Diabetes, Endocrinology and Metabolism Fukushima Medical University Fukushima Japan.ORCID 0000-0001-7835-7665
Moritake HigaDiabetes and Life-Style Related Disease Center Tomishiro Central Hospital Okinawa Japan.
Kazuaki ShimamotoSapporo Medical University School of Medicine Sapporo Japan.
Shigeyuki SaitoSapporo Medical University School of Medicine Sapporo Japan.
Makoto DaimonGlobal Center of Excellence Program Study Group Yamagata University School of Medicine Yamagata Japan.
Takamasa KayamaDepartment of Advanced Medicine Yamagata University School of Medicine Yamagata Japan.
Mitsuhiko NodaDepartment of Diabetes, Metabolism and Endocrinology Ichikawa Hospital International University of Health and Welfare Chiba Japan.
Sadayoshi ItoDivision of Nephrology, Endocrinology and Vascular Medicine Department of Medicine Tohoku University Hospital Miyagi Japan.
Koutaro YokoteDepartment of Endocrinology, Hematology and Gerontology Graduate School of Medicine Chiba University Chiba Japan.
Chikako ItoGrand Tower Medical Court Life Care Clinic Hiroshima Japan.
Kazuwa NakaoMedical Innovation Center Kyoto University Graduate School of Medicine Kyoto Japan.
Toshimasa YamauchiDepartment of Diabetes and Metabolic Diseases Graduate School of Medicine The University of Tokyo Hospital Tokyo Japan.
Takashi KadowakiDepartment of Diabetes and Metabolic Diseases Graduate School of Medicine The University of Tokyo Hospital Tokyo Japan.
University of Tokyo Hospital · JPKanazawa Medical University · JPKyushu University · JPNational Cerebral and Cardiovascular Center · JPSapporo Medical University · JPThe University of Osaka · JPYamagata University · JPChiba University · JPFukushima Medical University · JPHigashihiroshima Medical Center · JPInternational University of Health and Welfare · JPKeio University · JPKyoto University · JPOita University · JPOsaka International Cancer Institute · JPRadiation Effects Research Foundation · JPTohoku University Hospital · JPTomishiro Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background It is uncertain whether risk classification under the nationwide program on screening and lifestyle modification for metabolic syndrome captures well high-risk individuals who could benefit from lifestyle interventions. We examined the validity of risk classification by linking the incidence of cardiovascular disease (CVD). Methods and Results Individual-level data of 29 288 Japanese individuals aged 40 to 74 years without a history of CVD from 10 prospective cohort studies were used. Metabolic syndrome was defined as the presence of high abdominal obesity and/or overweight plus risk factors such as high blood pressure, high triglyceride or low high-density lipoprotein cholesterol levels, and high blood glucose levels. The risk categories for lifestyle intervention were information supply only, motivation-support intervention, and intensive support intervention. Sex- and age-specific hazard ratios and population attributable fractions of CVD, which were also further adjusted to consider non-high density lipoprotein cholesterol levels, were estimated with reference to nonobese/overweight individuals, using Cox proportional hazard regression. Since the reference category included those with risk factors, we set a supernormal group (nonobese/overweight with no risk factor) as another reference. We documented 1023 incident CVD cases (565 men and 458 women). The adjusted CVD risk was 60% to 70% higher in men and women aged 40 to 64 years receiving an intensive support intervention, and 30% higher in women aged 65 to 74 years receiving a motivation-support intervention, compared with nonobese/overweight individuals. The population attributable fractions in men and women aged 40 to 64 years receiving an intensive support intervention were 17.7% and 6.6%, respectively, while that in women aged 65 to 74 years receiving a motivation-support intervention was 9.4%. Compared with the supernormal group, nonobese/overweight individuals with risk factors had similar hazard ratios and population attributable fractions as individuals with metabolic syndrome. Conclusions Similar CVD excess and attributable risks among individuals with metabolic syndrome components in the absence and presence of obesity/overweight imply the need for lifestyle modification in both high-risk groups.

Indexed as

Cardiovascular DiseasesMetabolic SyndromeObesityAdultAgedFemaleHumansIncidenceJapanMaleMiddle AgedPrevalenceProspective StudiesRisk Assessmentcardiovascular diseasecohort studyincidencemetabolic syndromerisk classification

Identifiers

PMID34796738
PMCPMC9075363
OpenAlexW3211697849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.